



Co-funded by the
European Union

The project „Genomic surveillance of selected infectious diseases in the Czech Republic“ (HERA2CZ) is co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the European Health and Digital Executive Agency (HADEA) can be held responsible for them.

Disclaimer

This deliverable has been submitted to the European Commission and is currently under review.

The final version after the approval may differ.

D1.6 – Complementarity Strategy

<i>Project Title:</i>	<i>Genomic surveillance of selected infectious diseases in the Czech Republic</i>
<i>Project Acronym:</i>	<i>HERA2CZ</i>
<i>Project ID:</i>	<i>Grant Agreement - Project 101113387</i>
<i>Type of action:</i>	<i>EU4H Project Grants</i>
<i>Call:</i>	<i>EU4H-2022-DGA-MS-IBA-1</i>
<i>Topic:</i>	<i>EU4H-2022-DGA-MS-IBA-01-02</i>
<i>Beneficiary:</i>	<i>National Institute of Public Health, the Czech Republic</i>
<i>Coordinator:</i>	<i>Jana Kozáková, MD</i>
<i>Authors of the Deliverable:</i>	<i>Jana Kozáková (WP1), Helena Jiřincová (WP2), Martina Bielaszewska (WP3), Jana Kozáková (WP4), Helena Žemličková (WP5), Markéta Šimková</i>
<i>Date of the Deliverable:</i>	<i>25 March 2024</i>

National Institute of Public Health

Genomic surveillance of selected infectious diseases in the Czech Republic, HERA2CZ

Project: 101113387 — HERA2CZ — EU4H-2022-DGA-MS-IBA-1

D1.6 – Complementarity Strategy

Disclaimer



Co-funded by the
European Union

Co-Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or of the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the European Health and Digital Executive Agency (HADEA) can be held responsible for them.

Dissemination Level

PU	Public	<input type="checkbox"/>
SEN	Sensitive	<input checked="" type="checkbox"/>

History of Changes

Version	Date	Name	Chapters edited	Changes tracked
v1	25/03/2024	<i>J. Kozáková, H. Jiřincová, M. Bielaszewska, O. Daniel, P. Křížová, H. Žemličková, V. Jakubů, M. Šimková</i>	All	Document prepared

National Institute of Public Health

Genomic surveillance of selected infectious diseases in the Czech Republic, HERA2CZ

Project: 101113387 — HERA2CZ — EU4H-2022-DGA-MS-IBA-1

D1.6 – Complementarity Strategy

List of Abbreviations

AMR	<i>Antimicrobial Resistance</i>
ARI	<i>Acute Respiratory Infections</i>
ARI/ILI surveillance	<i>Acute Respiratory Infection and Influenza-Like Illness Surveillance National System</i>
CCRE	<i>Carbapenem and/or Colistin Resistant Enterobacterales</i>
CNV	<i>Copy Number Variants</i>
EQA	<i>External Quality Assessment</i>
FWD	<i>Food- And Water-Borne Diseases</i>
GISRS	<i>Global Influenza Surveillance and Response System</i>
GSD	<i>Genetic Sequence Data</i>
ILI	<i>Influenza-Like Illnesses</i>
IVPP	<i>Influenza Viruses with Human Pandemic Potential</i>
MDR	<i>Multidrug Resistant Bacteria</i>
MLST	<i>Multilocus Sequence Typing</i>
MPXV	<i>Monkeypox Viruses</i>
NIPH	<i>National Institute of Public Health</i>
NRLs	<i>National Reference Laboratories</i>
PC	<i>Partnership Contribution</i>
PIP	<i>Pandemic Influenza Preparedness</i>
QC	<i>Quality Control</i>
RSV	<i>Respiratory Syncytial Viruses</i>
RT-PCR	<i>Reverse Transcription Polymerase Chain Reaction</i>
SARI	<i>Severe Acute Respiratory Infections</i>
SMTA2	<i>Standard Material Transfer Agreements</i>
SNP	<i>Single Nucleotide Polymorphism</i>
SV	<i>Structural Variants</i>
WGS	<i>Whole Genome Sequencing</i>
WHE	<i>WHO Health Emergencies Programme</i>

1. Executive Summary

The complementarity strategy for sharing sequencing data was designed to explain current situation in data collection, management and sharing practices within the field of genomics at the National Institute of Public Health (NIPH) in the Czech Republic. Primary objective of this institution is to prevent pandemics and promote public health, secondary objectives are to promote research, enhance patient care, and uphold security and ethical standards. This strategy is relevant to HERA2CZ project which fosters technological preparedness of National Reference Laboratories (NRLs), encourages data sharing, and ensures the responsible and transparent utilization of genomic information while remaining in compliance with privacy regulations that ensures patient rights.

The submission of **the Complementarity strategy** (D1.6), coincides with **the Sustainability strategy** (D1.5). These two strategic documents are pivotal in ensuring that the HERA2CZ project's outcomes will not only endure but also remain accessible and operational over the long term. This strategy is also summarising the progress in the field during the project realisation and expected development in near future. For better readability of the strategy, the document was divided into three main parts (i) *Projects' baseline*, describing the initial situation before the project started, (ii) *Project phase*, explaining changes that are underway grace to the project realisation and the last section: (iii) *Future outlook*, that summarises future development expectations

The Complementarity strategy of HERA2CZ outlines the following aspects:

Projects' Baseline:

- **Legislative Background** - Explores the existing national and international legal framework relevant to HERA2CZ project.
- **Laboratory Equipment** – Assess the disponsible relevant laboratory equipment at the beginning of the HERA2CZ project.
- **Technological Infrastructure for Data Sharing** - Describes the disponsible relevant IT equipment at the beginning of the HERA2CZ project.
- **Security and Data Storage** – Describes the data storing techniques before the project's start.
- **Personnel**: Discusses the current situation of personal resources and specialisation needed.
- **Data Processing Procedures**: Outlines the procedures for handling sequencing data, including data processing, and storage.
- **Expected Development**: Provides insights into the anticipated developments and advancements in sequencing technologies, strategies and legislation and/or data management practices.
- **Data Standardization, Procedures, Formats, and Data Quality Control**: Overview of the data formats, procedures, and quality control measures to ensure consistency and reliability in sequencing data.
- **State-of-the-Art of Data Sharing**: definition of the current situation where are data shared and stored on national and international level.

National Institute of Public Health

Genomic surveillance of selected infectious diseases in the Czech Republic, HERA2CZ

Project: 101113387 — HERA2CZ — EU4H-2022-DGA-MS-IBA-1

D1.6 – Complementarity Strategy

Project Phase:

- **Handling of Data Generated in the Project:** Discuss changes during the project realisation and overview the possibilities in process automation.
- **Automation, Applications, New Tools for Data Visualization:** discuss application of new technical features within the HERA2CZ project.

Future Outlook

- **Better Data Management:** Discuss the impact of the project on improvement of the data management.
- **Inclusion of the Data to the ECDC Reporting:** Outlines, how the data generated in the project will be included in ECDC's regular reporting and how and where they will be published.

Upon the completion of the project, the D1.9 - **Sequencing Data Sharing Report** will serve as a comprehensive summary of the progress and achievements realized throughout the project's duration. This report will not only show the progress made but also provide a valuable resource for future efforts in genomics data sharing or to data sharing within the healthcare sector in general.